ERD

Periodic Reporting for period 4 - ESCALON (European-Latin American network for the assessment of biomarkers to predict a...

Project: ESCALON

Updated at: 31-08-2024

Show more information

Project acronym ESCALON

Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and...

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on the use of exoDNA as a biomarker for GBC

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Final dissemination report

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantati...

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by...

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on risk factors in individuals with predisposing factors for CCA

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on clinical and genetic parameters as risk factors for HCC

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Exploitation report

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations f...

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Newsletters every 6 months (8 in total) with project news and findings

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adeno...

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report of immune-phenotypic and functional markers in GBC patients of Amerindian and non Amerindian ancestry

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Cryptogenic non‑cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiology.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

"""Hepatitis C and hepatocellularcarcinoma in Latin America: Elimination as a path to cancer prevention."""

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on validation of the protein signature described in deliverable D2.1 to diagnose CCA in individuals at risk

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on risk factors related to HCC development in NAFLD patients.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Policy briefs for prevention and screening of HCC, CCA and GBC

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on the proteomic signature to diagnose CCA in individuals at risk

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on HBV-related risk factors leading to early HCC in Latin America.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on serum biomarkers to predict HCC in individuals at risk.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on serum protein levels in GBC patients of Amerindian and non Amerindian ancestry

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Exploring the Promise of Second-Line Chemotherapy in Biliary Tract Tumours: A Glimpse into Novel Treatment Approaches.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on distinctive protein signatures to identify intrahepatic CCA versus HCC

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Report on the content of the first Latin-American database of CCA

Project: ESCALON

Updated at: 29-04-2024

Show more information

Project acronym ESCALON

Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays

Project: ESCALON

Updated at: 01-01-2024

Show more information

Project acronym ESCALON

PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation.

Project: ESCALON

Updated at: 01-01-2024

Show more information

Project acronym ESCALON

Resources

Selected filters:

Periodic Reporting for period 4 - ESCALON (European-Latin American network for the assessment of biomarkers to predict a...

Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and...

Report on the use of exoDNA as a biomarker for GBC

Final dissemination report

The Role of PIVKA-II as a Predictor of Early Hepatocellular Carcinoma Recurrence-Free Survival after Liver Transplantati...

Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by...

Report on risk factors in individuals with predisposing factors for CCA

Report on clinical and genetic parameters as risk factors for HCC

Exploitation report

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations f...

Newsletters every 6 months (8 in total) with project news and findings

Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adeno...

Report of immune-phenotypic and functional markers in GBC patients of Amerindian and non Amerindian ancestry

Cryptogenic non‑cirrhotic HCC: Clinical, prognostic and immunologic aspects of an emerging HCC etiology.

"""Hepatitis C and hepatocellularcarcinoma in Latin America: Elimination as a path to cancer prevention."""

Report on validation of the protein signature described in deliverable D2.1 to diagnose CCA in individuals at risk

Report on risk factors related to HCC development in NAFLD patients.

Policy briefs for prevention and screening of HCC, CCA and GBC

Report on the proteomic signature to diagnose CCA in individuals at risk

Report on HBV-related risk factors leading to early HCC in Latin America.

Report on serum biomarkers to predict HCC in individuals at risk.

Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma.

Report on serum protein levels in GBC patients of Amerindian and non Amerindian ancestry

Exploring the Promise of Second-Line Chemotherapy in Biliary Tract Tumours: A Glimpse into Novel Treatment Approaches.

Report on distinctive protein signatures to identify intrahepatic CCA versus HCC

Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.

Report on the content of the first Latin-American database of CCA

Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays

PFKFB4 Is a Metabolic Driver of HCC Progression and Chemoresistance Through ROS Mitigation.